EDAP TMS S.A. to Release 2005 Fourth Quarter and Year End Financial Results March 15, 2006
March 14 2006 - 8:00AM
PR Newswire (US)
LYON, France, March 6 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP), will release its fourth quarter and year end
financial results for the period ending December 31, 2005 on
Wednesday, March 15, 2006 after the market close. The company will
host a conference call to discuss the results and answer questions
from investors on Thursday, March 16, 2006, at noon Eastern Time,
6:00 p.m. Paris Time. Representing the Company on the call will be
Philippe Chauveau, Chairman of the Board, Hugues de Bantel, Chief
Executive Officer, and Thierry Turbant, Chief Financial Officer.
Interested investors may join the call live by dialing (888)
343-7143 from the United States or +1 (415) 537-1988 from
international locations and requesting the EDAP TMS Year End
Conference Call. Investors may also listen to the live call online
at http://www.edap-tms.com/ . Investors unable to join the call can
access a playback of the conference call by telephone or online. To
access the replay, please dial (800) 633-8284 or +1 (402) 977-9140
and using access code 21285198 beginning two hours after the end of
the call until March 23, 2006, or visit the company's Web site at
http://www.edap-tms.com/ . About EDAP TMS S.A. EDAP TMS S.A.
develops and markets Ablatherm, the most advanced and clinically
proven choice for High Intensity Focused Ultrasound (HIFU)
treatment of localized prostate cancer. HIFU treatment is shown to
be a minimally invasive and effective treatment option with a low
occurrence of side effects. The company is also developing this
technology for the treatment of certain other types of tumors. EDAP
TMS S.A. also produces and commercializes medical equipment for
treatment of urinary tract stones using Extra-corporeal Shockwave
Lithotripsy (ESWL). For more information on the Company, contact
the Investor Relations Dept by phone at +33 (0)4 78 26 40 46 or see
the Company's Web site at: http://www.edap-tms.com/ . This press
release contains, in addition to historical information,
forward-looking statements that involve risks and uncertainties.
These include statements regarding the Company's growth and
expansion plans. Such statements are based on management's current
expectations and are subject to a number of uncertainties and risks
that could cause actual results to differ materially from those
described in the forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described
in the Company's filings with the Securities and Exchange
Commission. Ablatherm-HIFU treatment is not yet FDA approved or
marketed in the United States. CONTACT: EDAP TMS S.A. Hugues de
Bantel - Philippe Chauveau Blandine Confort +33 4 78 26 40 46
Halliburton Investor Relations Matt Kreps - Geralyn DeBusk 972 458
8000 DATASOURCE: EDAP TMS S.A. CONTACT: Hugues de Bantel, Philippe
Chauveau or Blandine Confort, all of EDAP TMS S.A.,
+33-4-78-26-40-46; or Matt Kreps or Geralyn DeBusk, both of
Halliburton Investor Relations, +1-972-458-8000, for EDAP TMS S.A.
Web site: http://www.edap-tms.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024